会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • OXALIPLATIN NANOPARTICLES AND METHOD FOR PREPARING SAME
    • 奥沙利铂纳米颗粒及其制备方法
    • WO2011034394A3
    • 2011-11-03
    • PCT/KR2010006459
    • 2010-09-20
    • JW PHARMACEUTICAL CORPBIO SYNECTICS INCLEE SUNG JAEKIM YOUNG HOONLEE SANG HEONKIM KAB SIG
    • LEE SUNG JAEKIM YOUNG HOONLEE SANG HEONKIM KAB SIG
    • A61K9/16A61K9/20A61K33/24A61P35/00
    • A61K9/146A61K9/0095A61K9/10A61K9/2027A61K9/4866A61K31/555A61K47/38Y10T428/2982
    • The present invention relates to oxaliplatin nanoparticles, oxaliplatin being a water-soluble active substance, to a pharmaceutical composition comprising the nanoparticles, and to a method which involves emulsifying a lipid mixture solution, in which solid lipids and a surfactant are mixed, into an aqueous mixture solution in which oxaliplatin and a specific cosolvent are mixed, and removing the solid lipids and the cosolvent using supercritical fluid gas, to thereby prepare orally administrable nanoscale oxaliplatin particles. The oxaliplatin nanoparticles and method for preparing same according to the present invention are advantageous in that oxaliplatin nanoparticles, oxaliplatin being a water-soluble active substance, can be prepared in an economic manner using a supercritical fluid production facility which is relatively inexpensive, and oxaliplatin nanoparticles can be prepared with a high recovery factor through a simple process and can be easily commercialized. In addition, oxaliplatin, which has been thus-far prepared as injectable formulations, is prepared into nanoparticles to enable the development of oxaliplatin oral formulations which are safe to stomach acids and which have improved bioavailability, thereby preventing inconveniences and problems in using injectable formulations, and significantly contributing to the improvement of patient compliance and a reduction in medical expenses.
    • 本发明涉及奥沙利铂纳米颗粒,作为水溶性活性物质的奥沙利铂,包含该纳米颗粒的药物组合物,以及涉及将其中混合有固体脂质和表面活性剂的脂质混合物溶液乳化成水性 奥沙利铂与特定共溶剂混合的混合溶液,并且使用超临界流体气体除去固体脂质和共溶剂,由此制备可口服给药的纳米级奥沙利铂颗粒。 根据本发明的奥沙利铂纳米颗粒及其制备方法的优点在于奥沙利铂纳米颗粒奥沙利铂为水溶性活性物质,可以使用相对便宜的超临界流体生产设备以经济的方式制备,并且奥沙利铂纳米颗粒 可以通过简单的工艺以高回收率制备并且可以容易地商业化。 此外,将已经制备成可注射制剂的奥沙利铂制备成纳米颗粒,以开发对胃酸安全并且具有改善的生物利用度的奥沙利铂口服制剂,由此防止使用可注射制剂的不便和问题, 并为提高患者依从性和降低医疗费用作出了重大贡献。
    • 7. 发明申请
    • THE NOVEL BACILLUS AMYLOLIQUEFACIENS KTGB0202 AND CONTROL METHOD OF PLANT PATHOGENIC FUNZI USING THAT
    • 新型BACILLUS AMYLOLIQUEFACIENS KTGB0202及其使用该植物致病性FUNZI的控制方法
    • WO2005059112A1
    • 2005-06-30
    • PCT/KR2004/003203
    • 2004-12-07
    • KT & G CO., LTDKIM, Kab-SigYEO, Woon-Hyung
    • KIM, Kab-SigYEO, Woon-Hyung
    • C12N1/20
    • A01N63/00A01N63/02C12R1/07Y10S435/832
    • The present invention relates to a novel microorganism Bacillus amyloliquefaciens KTGB0202 and a method for controlling plant pathogens using the same. More particularly, the present invention relates to a novel microorganism Bacillus amyloliquefaciens KTGB0202 (accession number: KCTC 10564BP) bacterium which has an excellent control effect against crop powdery mildew and a broad spectrum of antifungal activity against plant pathogenic fungi and inhibits tobacco mosaic virus infection, as well as an eco-friendly bacterial culture broth for controlling powdery mildew, which contains the same. Also, the present invention relates to antifungal substance KTGB0202­AFO1 obtained by extraction and purification from the Bacillus amyloliquefaciens KTGB0202 bacteria. The inventive Bacillus amyloliquefaciens KTGB0202 bacteria have a broad spectrum of antifungal activity, and are excellent in activity continuance and used for controlling various plant pathogens, including powdery mildew.
    • 本发明涉及一种新型微生物解淀粉芽孢杆菌KTGB0202及其使用该植物病原体的方法。 更具体地说,本发明涉及一种对作物白粉病具有优异防除效果和对植物病原真菌的广谱抗真菌活性和抑制烟草花叶病毒感染的新型微生物解淀粉芽孢杆菌KTGB0202(登录号:KCTC 10564BP)细菌, 以及含有相同的防治白粉病的环保细菌培养液。 此外,本发明涉及通过从解淀粉芽孢杆菌KTGB0202细菌提取和纯化获得的抗真菌物质KTGB0202AFO1。 本发明的解淀粉芽孢杆菌KTGB0202细菌具有广谱的抗真菌活性,活性连续性优异,用于防治各种植物病原体,包括白粉病。